We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+7.98%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$6.25B
AUM Growth
-$1.7B
Cap. Flow
-$2.08B
Cap. Flow %
-33.31%
Top 10 Hldgs %
54.24%
Holding
331
New
77
Increased
88
Reduced
65
Closed
73

Top Buys

Rank Stock Value
1
FIVN icon
FIVE9
FIVN
+$41.6M
2
NARI
Inari Medical, Inc. Common Stock
NARI
+$39M
3
DPZ icon
Domino's
DPZ
+$33.2M
4
INCY icon
Incyte
INCY
+$27.6M
5
HUM icon
Humana
HUM
+$26.5M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$109M
2
EXAS
Exact Sciences
EXAS
+$59.2M
3
SNY icon
Sanofi
SNY
+$49.7M
4
KDP icon
Keurig Dr Pepper
KDP
+$49.6M
5
GSK icon
GSK
GSK
+$39.9M

Sector Composition

Rank Sector Weight
1 Healthcare 41.55%
2 Consumer Discretionary 7.13%
3 Consumer Staples 5.35%
4 Technology 5.24%
5 Communication Services 0.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CTM icon
276
Castellum
CTM
$60.4M
– –
-3,547,987
Closed -$660K
DPRO
277
Draganfly
DPRO
$169M
– –
-258,920
Closed -$1.51M
DRMA icon
278
Dermata Therapeutics
DRMA
$4.42M
– –
-2,800
Closed -$66.9K
DTE icon
279
DTE Energy
DTE
$29.3B
– –
-2,009
Closed -$223K
DXCM icon
280
DexCom
DXCM
$31.8B
– –
-8,328
Closed -$944K
ELAN icon
281
Elanco Animal Health
ELAN
$11.6B
– –
-14,811
Closed -$214K
ELTX icon
282
Elicio Therapeutics
ELTX
$83M
– –
-100,000
Closed -$411K
EXAS
283
DELISTED
Exact Sciences
EXAS
– –
-1,400,086
Closed -$59.2M
KYNB
284
CALL
Kyntra Bio
KYNB
$29.1M
– –
-40,000
Closed -$892K
FWRG icon
285
First Watch Restaurant Group
FWRG
$770M
– –
-185,000
Closed -$3.25M
GNLX icon
286
Genelux
GNLX
$118M
– –
-900,000
Closed -$1.75M
GNPX icon
287
Genprex
GNPX
$2.19M
– –
-198
Closed -$411K
GOVX icon
288
GeoVax Labs
GOVX
$4.04M
– –
-3,200
Closed -$255K
GRI
289
GRI Bio
GRI
$2.64M
– –
-105
Closed -$96.4K
GT icon
290
Goodyear
GT
$1.89B
– –
-10,049
Closed -$114K
HBM icon
291
Hudbay
HBM
$12.1B
– –
-10,770
Closed -$97.5K
HEPA
292
DELISTED
Hepion Pharmaceuticals
HEPA
– –
-10,320
Closed -$526K
RKTO
293
Rocket One Inc
RKTO
$19.9M
– –
-213,000
Closed -$194K
HSDT icon
294
Solana Company
HSDT
$99.8M
– –
-173
Closed -$127K
IOBT
295
DELISTED
IO Biotech
IOBT
– –
-1,545,000
Closed -$1.81M
IPW icon
296
iPower
IPW
$683K
– –
-677
Closed -$3.04M
K
297
DELISTED
Kellanova
K
– –
-451,544
Closed -$26M
KDP icon
298
Keurig Dr Pepper
KDP
$40.9B
– –
-1,486,063
Closed -$49.6M
KHC icon
299
Kraft Heinz
KHC
$29.9B
– –
-7,457
Closed -$240K
KO icon
300
Coca-Cola
KO
$374B
– –
-171,244
Closed -$10.9M
10 11
12
13 14

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return
DSC
Donald Smith & Co New York $5.56B AUM 47.13% 1-Year Est. Return
ACM
Altimeter Capital Management Boston, Massachusetts $5.7B AUM 36.74% 1-Year Est. Return
PI
PGGM Investments Zeist, Netherlands $5.7B AUM 17.05% 1-Year Est. Return

Armistice Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Armistice Capital held 331 positions worth $6.25B, down 21% from $7.95B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Armistice Capital withdrew a net $2.08B in Q3 2024, closing 73 positions and reducing 65 holdings. Its most notable exit was Exact Sciences, an estimated $59.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 33% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

Against the trend, Armistice Capital opened a new position in Paramount Global Class B worth $21.2M.

  • Armistice Capital's largest Q3 2024 buy was Paramount Global Class B: 2,000,000 shares worth $21.2M.
  • Armistice Capital added most to FIVE9 in Q3 2024, an estimated $41.6M increase.
  • Armistice Capital's biggest Q3 2024 reduction was Neurocrine Biosciences, cutting an estimated $109M.
  • Armistice Capital fully exited Exact Sciences in Q3 2024, selling an estimated $59.2M.
  • Armistice Capital's ten largest holdings make up 54% of its $6.25B portfolio in Q3 2024.
  • Armistice Capital opened 77 new positions and closed 73 in Q3 2024.
  • Armistice Capital's portfolio value fell 21% quarter-over-quarter to $6.25B.

Based on Armistice Capital's 13F filing for Q3 2024, filed 14 Nov 2024.